DEPARTMENT OF HEALTH & HUMAN SERVICES



MAY 9 2007

Food and Drug Administration Rockville MD 20857

Re: Mycamine – NDA 21-754 Patent Nos. 6,107,458 and 6,265,536 Docket Nos. 2006E-0023 and 2006E-0345

The Honorable Jon Dudas
Under Secretary of Commerce for Intellectual Property
Director of the United States Patent and Trademark Office
Mail Stop Hatch-Waxman PTE
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Director Dudas:

This is in regard to the patent term extension applications for U.S. Patents No. 6,107,458 and 6,265,536 filed by Astellas Pharma, Inc. under 35 U.S.C. § 156. The patents claim Mycamine (micafungin sodium), NDA 21-754.

In the September 20, 2006, issue of the <u>Federal Register</u> (71 Fed. Reg. 54994), the Food and Drug Administration published its determination of this product's regulatory review period, as required under 35 U.S.C. § 156(d)(2)(A). The notice provided that on or before March 19, 2007, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. § 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to this notice has expired and FDA has received no such petition. Therefore, FDA considers the regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

/Jane A. Axelrad

Associate Director for Policy

Center for Drug Evaluation and Research

- a. appliat

cc: Stephen G. Baxter

Oblon, Spivak, McClelland, Maier, & Neustadt, PC

Customer No. 22850 1940 Duke Street

Alexandria, VA 22314